Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.50 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.50 |
| ▸ | TUBB | P07437 | 1/20 | 0.50 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.50 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.50 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.50 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.50 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.50 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.50 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.50 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.50 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.50 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.50 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL365644 | 0.98 | TAAR1 (0.61) | TAAR1MAOBCALM1IDO1AOC3 | |
| SCHEMBL11711227 | 0.91 | MAOB (0.66) | TAAR1MAOBCALM1IDO1AOC3 | |
| SCHEMBL1796734 | 0.84 | CALM1 (0.62) | TAAR1MAOBCALM1IDO1AOC3 | |
| SCHEMBL834551 | 0.83 | TAAR1 (0.73) | TAAR1MAOBCALM1IDO1AOC3 | |
| SCHEMBL5252007 | 0.83 | CALM1 (0.60) | TAAR1MAOBCALM1IDO1AOC3 | |
| SCHEMBL467215 | 0.81 | IDO1 (0.56) | TAAR1CALM1IDO1SIGMAR1CA12 | |
| SCHEMBL8693900 | 0.81 | CALM1 (0.58) | TAAR1MAOBCALM1IDO1AOC3 | |
| SCHEMBL8693901 | 0.81 | CALM1 (0.58) | TAAR1MAOBCALM1IDO1AOC3 | |
| Methylamine SCHEMBL9740790 | 0.81 | TAAR1 (0.59) | TAAR1MAOBCALM1IDO1AOC3 | |
| SCHEMBL6610916 | 0.81 | CALM1 (0.58) | TAAR1MAOBCALM1IDO1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951793-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1656368-A4 | SUBSTITUTED HERTOCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20070287713-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-7279485-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1656368-A2 | SUBSTITUTED HERTOCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20040063700-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004004665-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287713-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | PYM1, GPR119, GLP1R | TAAR1 2759/4885MAOB 1269/4885CALM1 3766/4885 |
| US-20040063700-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | GPR119, SLC5A2, GLP1R | TAAR1 2993/4885MAOB 2233/4885CALM1 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.